Different Clinical Utility of Oropharyngeal Bacterial Screening prior to Percutaneous Endoscopic Gastrostomy in Oncological and Neurological Patients

Table 4

Univariate analysis of possible risk factors with respect to the PEG site infection in all patients and separately for head and neck cancer patients and neurological patients. Statistically significant at 5% level.

Variable	All ()			Cancer ()			Neurological ()
	OR	95% CI		OR	95% CI		OR	95% CI
Sex (male)	1.49	0.65–3.39	0.330	1.03	0.27–3.85	0.969	0.46	0.17–1.24	0.126
PEG indication (cancer)	2.24	0.95–5.26	0.070		n.a.			n.a.
Colonizing pathogens	1.52	0.59–4.07	0.408	8.33	1.66–41.76	0.010*	0.75	0.25–2.22	0.601
Polymicrobial flora	0.76	0.30–1.90	0.678	3.00	0.73–12.34	0.128	0.47	0.15–1.49	0.199
Pathogens resistant to amoxicillin	0.92	0.39–2.15	1.000	1.74	0.39–7.71	0.466	0.97	0.37–2.57	0.950
MRSA colonization	3.28	0.64–14.80	0.107		n.a.		4.50	1.08–18.76	0.039*
Serious comorbidities	1.24	0.39–3.71	0.781	0.76	0.08–6.94	0.806	1.63	0.50–5.32	0.416
Tracheostomy	0.87	0.34–2.17	0.834	1.53	0.35–6.70	0.570	0.78	0.27–2.29	0.653
Other complications	0.93	0.21–3.54	1.000	0.37	0.04–3.19	0.367	1.44	0.30–6.87	0.646

n.a.: cannot be evaluated.